Developing biosimilars of medicines that are due to come off patent could save the NHS up to £40m per year on average, a Medicines UK report has said
@pharmaj.bsky.social
@pharmaj.bsky.socialDeveloping biosimilars of medicines that are due to come off patent could save the NHS up to £40m per year on average, a Medicines UK report has said
@antibodytx.bsky.socialAntibody Therapeutics (IF=4.8, Oxford University Press) ⚡ Research Highlight - A landscape of sequence variants in 51 commercial antibody therapeutics.
doi.org/10.1093/abt/...
#antibodydiscovery #antibodytherapeutics #biologics #sequencevariant #biosimilar #massspectrometry
@newsen.bsky.socialBiocon Achieves Positive CHMP Opinion for Pertuzumab Biosimilar, A First Under EMA’s New Clinical Approach #India #Bengaluru #Biocon #Biosimilar #Pertuzumab
@newsen.bsky.socialBiocon's Pertuzumab Biosimilar Receives Positive CHMP Opinion Under EMA's New Development Approach #India #Bengaluru #Biocon #Biosimilar #Pertuzumab
@council4ip.bsky.socialThis article perpetuates the claim that so-called "patent thickets" delay competition.
But the data doesn't support their existence.
According to the #USPTO, there is no evidence that the number of #patents covering a #medicine affects the timing of #generic and #biosimilar entry.
For more info: